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Abstract
Background:  Results from numerous studies point convincingly to correlations between
mutations at selected genes and phenotypic resistance to antimalarials in Plasmodium falciparum
isolates. In order to move molecular assays for point mutations on resistance-related genes into
the realm of applied tools for surveillance, we investigated a selection of P. falciparum isolates that
were imported during the year 2001 into Europe to study the prevalence of resistance-associated
point mutations at relevant codons. In particular, we tested for parasites which were developing
resistance to antifolates and chloroquine. The screening results were used to map the prevalence
of mutations and, thus, levels of potential drug resistance in endemic areas world-wide.
Results: 337 isolates have been tested so far. Prevalence of mutations that are associated with
resistance to chloroquine on the pfcrt and pfmdr genes of P. falciparum was demonstrated at high
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levels. However, the prevalence of mutations associated with resistance to antifolates at the DHFR
and DHPS genes was unexpectedly low, rarely exceeding 60% in endemic areas.
Conclusions: Constant screening of imported isolates will enable TropNetEurop to establish a
screening tool for emerging resistance in endemic areas.
Background
In an increasing number of countries where malaria is en-
demic, the effectiveness of routinely administered antima-
larials like chloroquine and sulfadoxine/pyrimethamine
is severely reduced because of the multi-drug resistance of
Plasmodium falciparum. This poses a serious problem in
terms of treatment and prophylaxis. Yet, mainly for finan-
cial reasons, chloroquine remains the first-line drug for
treatment of malaria in these countries.
On the other hand, travelers from Europe and other in-
dustrialised countries, who have contracted Falciparum
malaria, are commonly treated, on their return home,
with highly effective antimalarials (usually mefloquine,
halofantrine or quinine) that are frequently not freely
available for routine treatment in endemic areas. There-
fore, drug resistance is as yet not a frequent problem in the
treatment of Falciparum malaria in hospitals of industri-
alized countries. Infected European travelers and immi-
grants carry a wide variety of P. falciparum strains from all
endemic areas. Data and parasite material gained from
this population, if properly used, can help to predict the
development of drug resistance in endemic areas.
Point mutations at several codons of Plasmodium falci-
parum genes have been associated with emergence of drug
resistance to commonly used antimalarial drugs. In partic-
ular, resistance to antifolates (e.g. pyrimethamine/sulf-
adoxine) and chloroquine depends on point mutations at
the Dihydrofolate Reductase (DHFR) and Dihydropter-
oate Synthetase (DHPS) or Pfcrt and Pfmdr1 genes, re-
spectively [1–3] . Several protocols for the detection of
relevant mutations have been developed and have been
evaluated with samples from endemic areas. Although a
clear correlation between parasite genotype and in vivo
outcome could not be documented in all field trials, the
results show convincingly that a selected parasite popula-
tion, if properly used, can help to correlations between
point mutations and phenotypic resistance distinguish
[4–9] . In order to move molecular assays for point muta-
tions on resistance-related genes into the realm of applied
tools for surveillance, we investigated a selection of P. fal-
ciparum isolates that were imported during the year 2001
into Europe to study the prevalence of resistance-associat-
ed point mutations at relevant codons. In particular, we
tested isolates which were developing resistance to anti-
folates and chloroquine. The screening results were used
for mapping prevalence of mutations and, thus, levels of
potential drug resistance in endemic areas.
Methods
The study was established within the infrastructure of the
European Network on Imported Infectious Disease Sur-
veillance (TropNetEurop) which has been successfully
providing surveillance data on imported malaria since
1999 [10] . The network covers approximately 12% of all
imported malaria cases in Western and Central Europe.
TropNetEurop is designed to effectively detect emerging
infections of potential regional, national or global impact
at their point of entry into the domestic population. Sen-
tinel Surveillance reporting is carried out by participating
sites using a standardized and computerized reporting
system. Immediate transmission of anonymized patient
and laboratory data to the central database assures timely
detection of sentinel events. The comprehensive collec-
tion of data on notifiable and non-notifiable infectious
diseases in travelers makes it possible to identify needs for
further surveillance and investigation and provides the
potential for future case-control studies by identification
of specific risk factors. The primary objectives of TropNe-
tEurop are a) to construct and maintain a collaborative re-
search network of clinical sites in Europe dealing with
imported infectious diseases and b) to establish and
maintain a clinical network for effective sentinel surveil-
lance of imported infectious diseases in Europe. Member-
ship is self-selected by participating centers and
monitored by the steering committee of the network. Al-
though the organization of the network does not guaran-
tee a representative data collection for Europe, most
referral centers in Europe are represented. From the begin-
ning, malaria has been one of the major targets within this
network of 38 clinical sites throughout 15 European
countries.
Detection of resistance-related point mutation followed
established protocols. During standard malaria testing by
thick and thin blood film, 10 l of full blood from each
patient were dotted on Whatman 3 MM® chromatography
paper and air-dried at room temperature before initiation
of treatment. DNA was prepared from the dried blood
spots as previously described [11] . For detection of the
single base change at codon 86 of Pfmdr1, a 330-basepair
DNA fragment was amplified and followed by restriction-
fragment-length-polymorphism (RFLP)-analysis [12,13] .
A nested PCR protocol was used to identify the K76T inMalaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/11
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the Pfcrt gene [8,14] . After amplification of a 145 bp frag-
ment around the codon 76, alleles carrying the K76 or T76
codon were discriminated by ApoI-restriction. For the de-
tection of polymorphisms on the DHFR and DHPS genes,
a previously described nested PCR method was used for
all samples [6,15] . A volume of 4 l of PCR product was
incubated with mutation specific restriction enzymes ac-
cording to the manufacturer's instructions (New England
Biolabs, Beverly, MA, USA).
DHFR gene digest
To discriminate the three alternatives of codon 108 from
each other, the 522 bp PCR product of the primer pair
M3-F/ was digested with the following enzymes: AluI to
detect the serine wild type (327 bp and 203 bp), BsrI to
detect asparagine (309 bp and 190 bp) and BstNI to detect
threonine (190 bp and 332 bp). The restriction site for
Tsp509I was destroyed by an 51-asparagine to 51-isoleu-
cine mutation (215 bp). Another PCR product was digest-
ed by XmnI to detect the 59-arginine mutation (162 bp).
DHPS gene digest
A 438 bp PCR product was digested by MnlI to detect 436-
serine (283 bp), while digestion with MspAI identified the
436-alanine mutation (410 bp). Codon 437 was exam-
ined by digestion with AvaII to detect 437-glycine (402
bp) and MwoI to identify 437-alanine (387 bp). FokI
served to distinguish between 540-lysine (404 bp) and
540-glutamic acid (320 bp). Another PCR product (436
bp) was digested by HindIII to identify the 436-phenyla-
lanine mutation (410 bp). A PCR product of 161 bp was
digested by BstUI to detect the 581-alanine wildtype (30
bp and 130 bp) and by BslI to discover 581-glycine muta-
tions (30 bp and 130 bp). In the same way, the PCR prod-
uct was digested by MwoI to identify 613-alanine (137 bp)
and by BsaWI to detect the 613-serine/threonine muta-
Figure 1
Proportion of point mutations related to chloroquine resistance in different regions of sub-Saharan Africa (percentage showing
proportion of mutation-positive samples from every geographical region)
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tion (130 bp). It was possible to differentiate 613-serine
from 613-threonine by digestion with AgeI, which cuts in
case of an 613-threonine mutation (128 bp).
All digestion products were separated by electrophoresis
in an 1% SeaKem™ plus 1% NuSieve™ gel (FMC BioProd-
ucts, Rockland, ME, USA). As representative controls we
used the established Plasmodium falciparum laboratory
clones K1 and FCR3 as well as three own isolates that were
gained during earlier studies in Uganda.
Results & Discussion
Altogether, 337 samples were screened (table 1). The ma-
jority (n = 313; 92.9%) of these were imported from sub-
Saharan Africa. Out of the 24 samples (7.1%) from other
endemic areas, 14 were from Indonesia. As the small
numbers of isolates from Asia and the Americas were only
of limited value for the determination of prevalence rates
of point mutations, we omitted these areas from further
evaluation. The total distribution of mutation-related
point mutations among all isolates is shown in table 2.
The mutation on Pfcrt76Lys/Thr has been identified as po-
tentially crucial for developing resistance, while
Pfmdr86Asn/Tyr appears to play a supporting role [16] .
The majority of samples from sub-Saharan Africa showed
at least former mutation (figure 1). However, a surprising-
ly high proportion of samples from areas that are general-
ly assumed to have a very high level of drug resistance
showed none of the mutations [17] . In particular, 40.2%
of all samples from West Africa lacked the crucial prereq-
uisite to develop phenotypical resistance to chloroquine
(figure 1). A combination of both mutations was only
present in 37.9% of the tested samples (data not shown).
This pattern became even clearer when testing for muta-
tions that are associated with resistance to antifolates.
Here, DHFR108Ser/Asp has been identified as crucial mu-
tation for resistance to group I antifolates, while
DHFR51Asp/Iso and DHFR59Cys/Arg have a supporting
Figure 2
Proportion of point mutations related to resistance to group I antifolates in different regions of sub-Saharan Africa (percentage
showing proportion of mutation-positive samples from every geographical region)
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Figure 3
Proportion of point mutations related to resistance to group II antifolates in different regions of sub-Saharan Africa (percent-
age showing proportion of mutation-positive samples from every geographical region)
Table 1: Molecular surveillance of malaria drug resistance: geographical distribution of all isolates (n = 337)
Region Number %
Central Africa 39 11.6
East Africa 53 15.7
Southern Africa 20 5.9
West Africa 198 58.8
Madagascar & African islands in the Indian Ocean 3 0.9
Central America 10 . 3
Caribbean 20 . 6
South America 00
West Asia 00
Indian Subcontinent 51 . 5
Indonesia 14 4.2
South East Asia 20 . 6
East Asia 00
Oceania 00
Total 337 100
38.5%
DHPS 436
Ser/Ala
DHPS 437
Ala/Gly
Mutations related to 
resistance against 
group II antifolates
DHPS 540
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0.7%
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function in enhancing the effect [1] . In similar fashion,
DHPS437Ala/Gly is viewed as prerequisite for resistance to
group II antifolates. Thus, P. falciparum has to gain muta-
tions on both genes in order to develop resistance to com-
bined antifolates, e.g. sulfadoxine/pyrimethamine. In the
random population of isolates gained from returning Eu-
ropean travelers, the distribution of the relevant muta-
tions across sub-Saharan Africa was comparatively low
(figures 2 and 3). The combination of triple mutations on
DHFR (108Ser/Asp, 51Asp/Iso and 59Cys/Ar) was found in
39.2% of samples in West Africa, 30.8% in Central, 42.9%
in East, and 33.3% in South Africa. The combination of
DHPS437Ala/Gly and DHPS 540Lys/Glu, which is viewed as
a necessary prerequisite for resistance to sulfonamides [9],
was prevalent in 3.4% of the samples imported from West
Africa, and 5.7% from East Africa, while no sample from
either Central Africa, or from South Africa showed the
combination. Thus, antifolates may still be effective in a
comparatively high percentage of isolates from these are-
as.
Conclusions
This type of molecular surveillance has very little effect on
treatment decisions for the individual travelers returning
with Falciparum malaria from endemic regions. However,
when used within a large clinical network, this method
has an unsurpassed advantage. It has become possible to
screen large numbers of isolates from malarious regions
that are collected randomly from travelers and are trans-
ported back to Europe. This study shows that the continu-
ous mapping of the patterns of resistance to crucial
antimalarials can be performed. Data gained by fast and
efficient molecular methods can be used as an early warn-
ing system for changes occurring in endemic areas, thus
providing additional information that may be crucial for
regional and international drug policy changes.
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